Core Insights - Principal Financial Group Inc. acquired 45,205 shares of Stoke Therapeutics, valued at approximately $1,062,000, representing about 0.08% of the company [2] - Several institutional investors have increased their stakes in Stoke Therapeutics, indicating growing interest in the company [3] - Research firms have provided positive ratings and price targets for Stoke Therapeutics, suggesting a favorable outlook for the stock [4] Institutional Investment - Marshall Wace LLP increased its position by 7.9%, owning 2,300,554 shares valued at $26,111,000 after acquiring an additional 168,771 shares [3] - Goldman Sachs Group Inc. raised its stake by 21.4%, now holding 1,662,039 shares worth $11,053,000 after purchasing 293,072 shares [3] - Assenagon Asset Management S.A. boosted its position by 67.3%, owning 900,272 shares valued at $21,156,000 after acquiring 362,299 shares [3] Analyst Ratings - Guggenheim initiated coverage with a "buy" rating and a price target of $60.00 [4] - JPMorgan Chase & Co. raised its price target from $15.00 to $25.00, maintaining a "neutral" rating [4] - The consensus rating for Stoke Therapeutics is "Moderate Buy" with a target price of $39.18 [4] Stock Performance - Stoke Therapeutics shares opened at $30.98, with a 52-week low of $5.35 and a high of $38.69 [5] - The company has a market capitalization of $1.77 billion and a PE ratio of 46.24 [5] - The 50-day moving average price is $31.54, while the 200-day moving average price is $27.33 [5] Insider Activity - Director Edward M. Md Kaye sold 13,430 shares at an average price of $32.27, resulting in a 21.47% decrease in his position [6] - General Counsel Jonathan Allan sold 3,978 shares at an average price of $32.28, leading to a 25.16% decrease in his ownership [6] - Over the last 90 days, insiders sold 58,302 shares valued at $1,826,430, with insiders owning 9.50% of the company's stock [6] Company Overview - Stoke Therapeutics is a clinical-stage biopharmaceutical company focused on developing genetic medicines for rare neuromuscular and neurological disorders [8] - The company utilizes its proprietary TANGO™ platform to design antisense oligonucleotides that enhance protein expression [8] - The lead program, STK-001, targets the sodium channel protein SCN1A for the treatment of Dravet syndrome [9]

Summary of Stoke Therapeutics Conference Call Company Overview - **Company**: Stoke Therapeutics (NasdaqGS:STOK) - **Focus**: Development of treatments for genetic diseases, specifically Dravet syndrome and Autosomal Dominant Optic Atrophy (ADOA) [2][6] Key Points on Dravet Syndrome - **Disease Understanding**: Dravet syndrome is a severe form of epilepsy affecting young children, leading to significant developmental challenges [2][3] - **Clinical Data**: Initial phase 1/2 data showed an 80% reduction in seizures on top of standard care medications, with durable effects observed over nearly four years [4][9] - **Cognitive and Behavioral Benefits**: Improvements in cognition and behavior were noted, measured by the Vineland-3 assessment, indicating potential for neurodevelopmental progress in children who typically plateau after 18 months [5][10] - **Phase 3 Program**: Enrollment for the phase 3 study is expected to complete in Q2 2026, with data anticipated in mid-2027 [6][28] Market Opportunity - **Patient Population**: Approximately 36,000-40,000 patients globally, with 16,000 in the U.S. and 6,000 currently addressable [50][51] - **Pricing Strategy**: The company aims to position its treatment as a disease-modifying therapy, potentially aligning pricing with similar therapies like Spinraza [52][54] Regulatory Pathway - **FDA Interaction**: The company is pursuing accelerated approval but faced challenges due to the FDA's request for additional data. A follow-up discussion is planned to present data against patient baseline rather than cross-study comparisons [34][35][36] - **Optimal Label**: The goal is to achieve a label that reflects both seizure reduction and cognitive improvements, which is crucial for market positioning and pricing discussions [41][42] ADOA Development - **New Indication**: The first patient for ADOA was dosed recently, targeting a genetic loss of eyesight by upregulating the OPA1 gene to improve mitochondrial function and vision [56][57] - **Market Size**: The ADOA market is estimated at around 16,000 patients in the top seven geographies [58] Financial Position - **Cash Reserves**: The company reported approximately $400 million in cash at the end of 2025, with funding from Biogen covering 30% of Dravet R&D costs, providing a runway into 2028 [60]

Core Insights - Stoke Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Dravet syndrome and ADOA using its TANGO RNA platform [1] Company Overview - The company is currently advancing Zorevunersen, which is in Phase 3 clinical trials and has presented four-year positive Open Label Extension (OLE) data [1]

Company Overview - Stoke Therapeutics (STOK) is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Dravet syndrome and ADOA using its TANGO RNA platform [1]. Product Development - The company’s lead product, Zorevunersen, is currently in Phase 3 clinical trials and has demonstrated positive four-year open-label extension (OLE) data [1]. - Another product in development is STK-002, aimed at addressing ADOA [1].

Summary of Stoke Therapeutics FY Conference Call Company Overview - **Company**: Stoke Therapeutics (NasdaqGS:STOK) - **CEO**: Ian Smith, in role since March 2025 - **Focus**: Upregulating protein expression for haplo-insufficient diseases, primarily targeting genetic conditions like Dravet syndrome and Autosomal Dominant Optic Atrophy (ADOA) [2][3] Key Developments - **Lead Medicine**: Zorevunersen, targeting Dravet syndrome by upregulating the SCN1A gene to increase NaV1.1 expression, aiming to reduce seizures and improve neurodevelopment [3][4] - **Clinical Trials**: - Currently in Phase 3 for Dravet syndrome with a target enrollment of 150 patients, approximately 60 patients have been randomized, and another 60 are in the screening phase [5][6] - Enrollment expected to complete by Q2 2026, with potential NDA submission in 2027 or early 2028 [6][20] - **Long-term Data**: Patients have been followed for up to four years, showing durability in seizure reduction (up to 85%) and improvements in neurocognition [7][10][18] Financial Position - **Funding**: Approximately $400 million available, sufficient to fund operations through 2028 [8][9] - **Collaboration**: Partnership with Biogen, which licensed commercial rights to zorevunersen and funds 30% of R&D development [21][22] Market Opportunity - **Patient Population**: Estimated 40,000 patients with Dravet syndrome across key geographies (15-20,000 in the U.S. and Europe) [20][21] - **Commercial Potential**: Anticipated robust demand for a disease-modifying treatment, with market research indicating high clinician willingness to prescribe [41][42] Regulatory Pathway - **Breakthrough Designation**: Zorevunersen has received this designation, allowing for expedited development discussions with the FDA [27][28] - **FDA Interaction**: Productive discussions with the FDA regarding the potential for filing based on Phase 1, 2, and OLE data, although the timeline for filing may not be significantly shortened [28][30] Pipeline and Future Plans - **Next Steps**: - Completion of Phase 3 enrollment and subsequent NDA filing [24][25] - Initiation of clinical trials for ADOA (STK-002) and SYNGAP1, with expectations for early efficacy results by the end of 2026 [50][51] - **Regulatory Strategy**: Focus on demonstrating improvement in vision for ADOA, which could shorten clinical study durations [52][53] Additional Insights - **Data Integrity**: Emphasis on the importance of long-term data and observed outcomes in regulatory discussions to support claims of disease modification [45][46] - **Market Positioning**: Differentiation from existing seizure medications by positioning zorevunersen as a true disease-modifying treatment [48][49] This summary encapsulates the critical points discussed during the Stoke Therapeutics FY Conference Call, highlighting the company's strategic focus, clinical advancements, financial health, and regulatory strategies.

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Zorevunersen for Dravet Syndrome - Stoke Therapeutics is advancing zorevunersen as a potential disease-modifying therapy for Dravet Syndrome[9] - Phase 3 study (EMPEROR) enrollment is expected to complete in Q2 2026 with data readout in mid-2027 to support NDA[12, 38] - Approximately 330 patients have been identified globally for the EMPEROR study, with ~60 in screening and ~60 randomized[12, 39] - Data from ongoing OLE studies show continuing improvements in cognition and behavior over 36 months[24] - Zorevunersen demonstrated significant reduction in major motor seizure frequency at 6 months compared to natural history data, with an 8248% reduction compared to a 2043% reduction in the natural history group (P=00181)[26] - In OLE studies, 86% of patients experienced CSF protein elevation, classified as a TEAE in 45%[31] STK-002 for Autosomal Dominant Optic Atrophy (ADOA) - A Phase 1 study of STK-002 for ADOA has been initiated in the UK and Europe[11] Financial Status and Collaboration - Stoke Therapeutics had approximately $3917 million in cash, cash equivalents, and marketable securities as of December 31, 2025, with funding anticipated into 2028[12] - A strategic collaboration with Biogen exists for the development and commercialization of zorevunersen, with Biogen holding exclusive commercialization rights outside of the US, Canada, and Mexico[48] - The Biogen collaboration includes $165 million upfront, shared development costs, and potential milestone payments of $385 million[49] Market Opportunity - There are approximately 38,000 patients with Dravet syndrome across 7 major markets[40, 44]

Clinical Development and Regulatory Pathways - The Company expects to complete enrollment of 150 patients in the second quarter of 2026, with a data readout in mid-2027 anticipated to support the submission of a New Drug Application (NDA) to the FDA[11] - The Company held a multidisciplinary meeting with the FDA to discuss the ongoing clinical development of zorevunersen, exploring potential expedited regulatory pathways, with ongoing discussions for additional information[11] - The Company plans to initiate a rolling NDA submission in the first half of 2027[11] - The Company anticipates that the ongoing EMPEROR study will provide critical data for future product development and regulatory submissions[5] - The Company is focused on advancing zorevunersen to treat Dravet syndrome, with expectations for significant clinical trial results[10] Financial Position and Projections - The Company has approximately $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which, combined with eligible proceeds from the Biogen collaboration, is expected to fund operations into 2028[11] - The preliminary financial information is subject to completion of financial closing procedures and may differ from actual results in the audited financial statements[6] Strategic Collaborations and Risk Management - The Company is collaborating with Acadia Pharmaceuticals and Biogen International to enhance its development activities and achieve strategic goals[10] - The Company is actively managing risks related to global business conditions, including inflation and geopolitical conflicts, which may impact operations[10] Intellectual Property Strategy - The Company is committed to protecting its intellectual property as part of its overall strategy for product commercialization[10]

Core Viewpoint - Stoke Therapeutics, Inc. is advancing its investigational medicine zorevunersen in collaboration with Biogen, targeting Dravet syndrome as a potential first-in-class disease-modifying treatment [1] Group 1: Company Overview - Stoke Therapeutics is focused on restoring protein expression through RNA medicine [1] - The company is developing zorevunersen as its lead investigational medicine [1] Group 2: Development Updates - The company announced accelerated timelines for the completion of enrollment in the clinical trial [1] - A Phase 3 data readout from the EMPEROR study is expected soon [1]

stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use. *Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD We ...